Downstream Processing Of A Mid-Scale Lentiviral Vector Batch For The Generation Of CAR-T Cells

By Dr. Franziska Bollmann and Michael Gohs, Sartorius

Chimeric antigen receptor (CAR) T-cells, which are specifically engineered to target and destroy malignant cells, have become a pivotal advancement in cancer immunotherapy. However, one of the major challenges in the efficient production of these genetically modified T cells, which form the foundation of CAR-T therapy, is the purification of lentiviruses. Currently, there is a lack of well-established technologies to facilitate the downstream processing of lentiviruses, which is a critical step in the manufacturing process. This application note aims to demonstrate the effectiveness of using tangential flow filtration (TFF) systems for the downstream processing of lentiviruses.

Discover how this approach not only simplifies the process but also enhances the overall efficiency and scalability of lentivirus purification in the context of CAR-T cell production.